DAPAGLIFOZINA NA INSUFICIÊNCIA CARDÍACA COM FRAÇÃO DE EJEÇÃO PRESERVADA: MECANISMOS DE AÇÃO, EVIDÊNCIAS CLÍNICAS E IMPLICAÇÕES TERAPÊUTICAS

• DOI: https://doi.org/10.22533/at.ed.45124120417

• Palavras-chave: Dapaglifozina. Insuficiência Cardíaca fração de ejeção preservada. Mecanismos de Ação. Evidências Clínicas.

• Keywords: Dapagliflozin. Heart Failure with Preserved Ejection Fraction. Mechanisms of Action. Clinical Evidence.

• Abstract: The chapter discusses heart failure with preserved ejection fraction (HFpEF), a prevalent condition, especially in the elderly, and explores the therapeutic potential of dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor. Evidence suggests that dapagliflozin may reduce symptoms and physical limitations in patients with HFpEF, highlighting its therapeutic relevance. The mechanisms of action of dapagliflozin are addressed, emphasizing its potential clinical benefit. Despite promising findings, gaps requiring further investigation to fully clarify the role of dapagliflozin in HFpEF and identify subgroups of individuals who may benefit are identified. The study suggests crucial implications for clinical practice, emphasizing the need for a multidisciplinary and continuous approach to managing this challenging condition. The methodology employed included a literature review conducted on scientific platforms such as SciELO, Google Scholar, and PubMed, with the selection of studies addressing the correlations between dapagliflozin and HFpEF. In light of this, relevant articles in English and Portuguese were examined by the authors for inclusion in the review. The results reveal a significant association between the mechanism of action of dapagliflozin and its therapeutic implications, indicating a reduction in HFpEF-related symptoms and improvement in physical limitations. Additionally, the beneficial effects of dapagliflozin on reducing blood pressure and improving cardiac function are discussed, with the potential to enhance the prognosis of patients with HFpEF. In summary, the study underscores the importance of adopting a multidisciplinary approach to explore the therapeutic implications of dapagliflozin and manage HFpEF. Further research is needed to fully elucidate the role of this medication and identify patients who will benefit most. These findings have significant implications for medical practice and may lead to improvements in the treatment and prognosis of HFpEF.